OptimizeRx Launches New Growth Phase Immediately Following Addition of Chief Commercial Officer
June 10 2019 - 8:31AM
OptimizeRx Corp. (NASDAQ: OPRX), a leading platform for
digital health messaging in the pharmaceutical industry, has added
three senior sales executives to its rapidly growing commercial
team. The new hires demonstrate the company’s focus on driving
growth and expanding its enterprise-level offerings.
“Todd, Eze and Adam are each proven
commercial sales leaders with strong records of
delivering enterprise-level solutions and addressing unmet needs
across the care continuum,” said Steve Silvestro, the
company’s recently added chief commercial officer. “By
further strengthening our commercial organization, we aim to
address the increasing demands of our core customer base within the
pharma industry. This focus aligns with our passion for improving
adherence and ultimately better outcomes for patients.”
According to a recent PWC
study, 52 percent of consumers with a high deductible
health plan say it would be hard to meet their deductible. This
cost burden will put further pressure on optimal outcomes for
patients thus highlighting the critical need for improved adherence
and financial solutions.
The OptimizeRx platform represents the
largest point-of-care network in the U.S. reaching over half the
ambulatory market. Through the company’s digital health platform,
pharma companies have critical access to doctors and their patients
to provide medication information and savings. The acquisition
of CareSpeak further enhances the platform’s capabilities
allowing OptimizeRx to meet the needs of expanded markets
in both health and hospital systems.
Samuelson, Abosi and Sokol add
years of experience in many facets of pharmaceutical
sales, innovation and commercialization, and have represented top
brands like Bayer, Decision Resources Group, Informa, IQVIA, and
Clarivate.
"The OptimizeRx platform and solution
suite uniquely delivers value for patients, healthcare providers
and life science manufacturers,”
said Eze Abosi. “Combining the company’s transparent
ROI, positive impact of its solutions on reducing healthcare costs
and the vision of our executive leadership team are key drivers of
my transition to the organization."
Added Adam Sokol: “Physicians are spending
more and more time within their EHR and less time with
pharmaceutical representatives. OptimizeRx allows
manufacturers, at the point-of-care, to engage physicians within
their EHR workflow. This is a powerful combination of value and
convenience for the patient, physician, and manufacturer.”
Commented Todd Samuelson: “We are seeing
a fantastic shift in the pharma industry – not only with
digital and technological advancement but with increasing focus on
the patient experience. Our efforts aim to educate physicians so
they can have more informed conversations with patients regarding
treatment options. No patient is the same,
and OptimizeRx has the tools and solutions to help
our pharma customers navigate those
complexities.”
For more information on OptimizeRx,
visit OptimizeRx.com.
About OptimizeRx
OptimizeRx® (Nasdaq: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest point-of-prescribe
promotional platform for the pharmaceutical
industry, OptimizeRx provides a direct channel
for pharma companies to communicate with healthcare
providers right within their workflow. The cloud-based solution
supports patient adherence to medications with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts
and Quest, and directly via its mobile communications
platform. For more information, follow the company
on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward
Looking Statements This press release contains
forward-looking statements within the definition of Section 27A of
the Securities Act of 1933, as amended, and such as in section 21E
of the Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx ContactDoug
Baker, CFOTel (248) 651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole
Brooks, Innsena CommunicationsTel (860) 800-2344nicolebrooks@innsena.com
Investor Relations ContactRon
Both, CMATel (949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024